Cambridge Healthtech Institute's Fifth Annual

CAR Ts, TCRs and TILs

( CAR-T、TCR、TIL )

Latest Innovations and Developments in Adoptive Cell Therapy

2018年5月2-3日 | World Trade Center | 马萨诸塞州波士顿

 

These are very exciting times for adoptive cell therapies. The FDA has approved the first two CAR Therapies for sale in the US, and momentum is already building behind the next generation of CARs, TCRs and TILs offering superior targeting and safety profiles. Cambridge Healthtech Institute's Fifth Annual CAR Ts, TCRs and TILs event will focus on the critical developments, clinical progress and latest research driving the delivery of adoptive cell therapies to the patient. Clinical progress with Chimeric Antigen Receptors (CAR), T Cell Receptors (TCR), and Tumor Infiltrating Lymphocytes (TIL) will be addressed in depth and new strategies for target discovery will be reviewed.


Final Agenda

Recommended Short Course(s)*

SC9: CAR T Cell Therapy for Solid Tumors

Soldano Ferrone, MD, PhD, Division of Surgical Oncology, Surgery, Massachusetts General Hospital, Harvard Medical School

Moonsoo M. Jin, PhD, Associate Professor, Molecular Imaging Innovations Institute, Radiology, Weill Cornell Medical College

Tara Arvedson, PhD, Director, Oncology Research, Amgen


*Separate registration required.

WEDNESDAY, MAY 2

7:30 am Registration and Morning Coffee

RECENT SUCCESS AND PROGRESS

8:30 Chairperson's Remarks

Mark Bonyhadi, PhD, Head, Research, Juno Therapeutics

8:40 KEYNOTE: Future Challenges in Adoptive T-Cell Therapy

Michel SadelainMichel Sadelain, PhD, Director, Center for Cell Engineering, Memorial Sloan Kettering Cancer Center



9:10 Development of Yescarta (Axicabtagene Ciloleucel), a First in Class CAR T Cell Product for Diffuse Large B Cell Lymphoma: A Translational Perspective

Adrian BotAdrian Bot, MD, PhD., Vice President, Translational Sciences, Kite, a Gilead Company

Yescarta (Axicabtagene Ciloleucel) is an anti-CD19 CAR T cell therapy that received recently approval for treatment of relapsing or refractory DLBCL. Yescarta met its primary endpoint with 82% objective response rate, 54% complete response and 44% ongoing response at 6 months. This presentation will describe key elements of the translational program, correlates of toxicities and durable objective response, product characteristics, patient conditioning, and importance of tumor microenvironment.

BCMA DIRECTED CAR Ts

9:40 Development of an Anti-BCMA CAR T Cell Therapy That Delivers Durable Clinical Responses in Relapsed/Refractory Multiple Myeloma

Molly PerkinsMolly Perkins, DPhil, Associate Director, Immunotherapy, bluebird bio

Our first anti-BCMA CAR T cell product candidate, bb2121, has demonstrated encouraging safety and efficacy in a Phase I trial for relapsed/refractory multiple myeloma. bb21217 is a second anti-BCMA clinical product candidate which is manufactured in the presence of a PI3k inhibitor, leading to a CAR T cell product enriched for potent, long-lived memory T cells. The preclinical and clinical data on bb2121 and bb21217 will be discussed, highlighting the key scientific lessons learned.

10:10 Coffee Break in the Exhibit Hall with Poster Viewing

10:55 CAR-Specific Activation and Kinetics of a BCMA-Directed CAR

Collin HauskinsCollin Hauskins, Research Scientist, Protein Sciences, Juno Therapeutics




 

Mark BonyhadiMark Bonyhadi, PhD, Head, Research, Juno Therapeutics

Reagents that specifically bind the CAR on genetically engineered cells may be used to detect and quantitate surface CAR expression, and can also be used to stimulate the CAR T cell directly through their engineered receptor. We describe the production of reagents that bind to CD19- and BCMA-directed CAR T cells. These reagents are capable of specifically activating and expanding CAR T cells, allowing us to interrogate the biology of CAR signaling. These reagents could have further applications in the manufacturing of CAR T cells.

OPTIMIZING CAR Ts 

11:25 Dual-Switch CAR T Cells: Orthogonal Molecular Switches to Control Activation and Elimination of Cancer-Targeted CAR T Cells

J. Henri BayleJ. Henri Bayle, PhD, Director of Molecular Biology, Research and Development, Bellicum Pharmaceuticals

Chimeric Antigen Receptor (CAR) therapies are effective against disseminated cancers but often lack control over T cell efficacy and persistence against off-tumor reactivity and excessive cytokine release. Two platforms were engineered to separate tumor antigen-targeted first-generation CARs from an inducible costimulatory component, iMyD88/CD40, and a pro-apoptotic safety switch based on Caspase-9. These switches are orthogonally controlled by high-affinity, cell-permeable ligands, rimiducid and rapamycin analogs that direct targeted protein oligomerization.

11:55 Carjacking CAR19 T Cells for Redirected Killing

Paul RennertPaul Rennert, PhD, President & CSO, Aleta Biotherapeutics Inc

CAR19 cellular therapeutics benefit from interaction with bona fide antigen-presenting B cells (both normal and malignant). The integration of fusion protein modules into CAR19 lentiviral constructs endows CACR19s with novel antigen recognition properties. These highly potent CARjacked CAR19s recognize both CD19 (directly) and novel antigens (redirected) enabling efficient cytotoxicity against diverse tumor types. The utility of this platform technology will be demonstrated for hematologic malignancies and solid tumors.

12:25 pm Sponsored Presentation (Opportunity Available)

12:55 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

1:55 Session Break

TCRs and TILs

2:10 Chairperson's Remarks

Adrian Bot, MD, PhD., Vice President, Translational Sciences, Kite, a Gilead Company

2:15 Optimized Manufacturing SPEAR TCR T-Cell Therapy for Solid Tumors

Mark DudleyMark Dudley, PhD, Senior Vice President, Bioprocessing & Development CMC, Technical Operations, Adaptimmune

Specific peptide enhanced antigen receptor (SPEAR) T-cells that are genetically re-targeted to tumors can be part of an effective therapy regimen for some refractory solid cancers. SPEAR T-cells targeting NY-ESO show promise in synovial sarcoma and other indications. MAGE-A10, MAGE-A4, and AFP are currently being evaluated in early phase clinical trials. Opportunities and challenges for optimizing a single cGMP platform to manufacturing products for multiple indications will be discussed.

2:45 Learning What Works from Successful Tumor Infiltrating Lymphocyte Therapy

Andrew SewellAndrew Sewell, PhD, Professor, Division of Infection and Immunity, Cardiff University School of Medicine

Over 20% of melanoma patients that have been refractory to other treatments undergo complete lasting remission after adoptive cell transfer of tumor-infiltrating lymphocytes (TILs). Dissection of these extraordinary successes by examining the dominant tumor-reactive T-cell clonotypes in the TIL infusion product and patient blood after 'cure' has revealed some surprising, exciting new HLA-restricted and non-HLA restricted targets that are expressed by many other tumour types.

3:15 Sponsored Presentation (Opportunity Available)

3:45 Refreshment Break in the Exhibit Hall with Poster Viewing

4:45 Problem-Solving Breakout Discussions

5:45 Networking Reception in the Exhibit Hall with Poster Viewing

7:00 End of Day

THURSDAY, MAY 3

8:00 am Morning Coffee

Combining Innate and Adaptive Immunity

8:30 Chairperson's Remarks

Bob Valamehr, PhD, Vice President, Cancer Immunotherapy, Fate Therapeutics

8:35 Adaptive NK Cells and Off-the-Shelf NK Cells to Treat Cancer

Jeffrey S. MillerJeffrey S. Miller, MD, Professor of Medicine, Deputy Director, Masonic Cancer Center, Division of Hematology, Oncology and Transplantation, University of Minnesota University of Minnesota

Cytomegalovirus exposure is uniquely associated with the expansion of natural killer (NK) cells that express NKG2C and the maturation marker CD57. Adaptive NK cells are epigenetically primed for enhanced anti-tumor activity alone and in combination with CD16 signaling. Clinically, adaptive NK cells should result in superior anti-cancer effectors from CMV+ donors or from off the shelf iPS derived NK cells genetically modified to mimic functional attributes of adaptive NK cells.

9:05 Combining Innate and Adaptive Immunity: NK Receptors for CAR T Cell Therapy

David GilhamDavid Gilham, PhD, Vice President, Research, Celyad

Natural Killer cells possess innate capacity to target 'abnormal' cells through the recognition of a range of target ligands, many of which are present on tumor cells. Engineering NK receptors into a CAR format and expressing in T cells takes advantage of both NK specificity and T cell effector functionality. This approach will be discussed in the context in the pre-clinical setting and discussion of on-going clinical trials testing this approach.

9:35 Sponsored Presentation (Opportunity Available)

10:05 Coffee Break in the Exhibit Hall with Poster Viewing

Off-the-Shelf Cancer Immunotherapy

11:05 Pluripotent Cell Derived T and NK Cells: Cornerstone Approach for Off-the-Shelf Cancer Immunotherapy

Bob ValamehrBob Valamehr, PhD, Vice President, Cancer Immunotherapy, Fate Therapeutics

Pluripotent cell technology represents a powerful approach to make cell-based immunotherapies available to a wide range of patients through the generation of a consistent and renewable "off-the-shelf" source of cellular therapeutics. I will discuss our progress towards developing unique and effective strategies to create a renewable source of genetically engineered "off-the-shelf" T and NK cells with augmented function. Updates on IND filings and FIH progress will also be given.

11:35 Continuously Growing NK Cell Line as a Source for an Off-the-Shelf, Engineered NK Cell Therapeutic in Cancer and Infections

Hans KlingemannHans Klingemann, MD, PhD, Vice President, Research & Development, NantKwest, Inc.

NantKwest has developed the NK cell line NK-92 into an "off the shelf" activated NK (aNK) cell therapeutic. The safety of aNK as well as their activity against a broad range of cancers have been confirmed in several Phase I clinical trials. The aNK cells can be administered in the outpatient setting and serve as a universal cell-based therapy without need for individualized patient matching. The aNK cell platform has been bioengineered to incorporate a high-affinity antibody binding Fc-receptor (haNK). Both aNK and haNK cells can be equipped with chimeric antigen receptors (CARs) (called taNK) to further optimize targeting and potency.

12:05 pm Progress in Tumor Infiltrating Lymphocytes in Treatment of Solid Tumors

Maria FardisMaria Fardis, PhD, CEO, Iovance

Iovance Biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). In Phase 2 clinical trials conducted at the NCI, 56% and 24% of patients treated with this technology were reported by NCI to have achieved objective and complete response criteria, respectively. Our lead product candidate is an autologous, ready-to-infuse cell therapy, that has demonstrated distinctive efficacy in the treatment of metastatic melanoma.

12:35 End of CAR Ts, TCRs and TILs

* 活动内容有可能不事先告知作更动及调整。

Choose your language
Chinese
Japanese
Korean
English

Premier Sponsors

Genedata

GenScript CRO Logo

Harbour Biomed

 LONZA tagline

Nanotemper Technologies

Pall Life Sciences

Precision for Medicine 

Schrodinger 

赞助商

媒体合作夥伴